RANI Rani Therapeutics
- 5.250
- +0.030+0.57%
- 5.390
- +0.140+2.67%
Rani Therapeutics News
UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating
Rani Therapeutics Holdings (RANI) has an average rating of Buy and price targets ranging from $8 to $14, according to analysts polled by Capital IQ.
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Rani Therapeutics Price Target Raised to $14.00/Share From $7.00 by BTIG
Rani Therapeutics Price Target Raised to $14.00/Share From $7.00 by BTIG
BTIG: Maintaining the Rani Therapeutics Hldgs (RANI.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $14.00.
BTIG: Maintaining the Rani Therapeutics Hldgs (RANI.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $14.00.
BTIG Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $14
BTIG analyst Robert Hazlett maintains Rani Therapeutics Hldgs with a Buy and raises the price target from $7 to $14.
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv
Edward Nash Maintains Buy Rating on Rani Therapeutics Amid Strong Financials and Promising Clinical Trials
Rani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates
Rani Therapeutics Reports Q1 Results
Rani Therapeutics Holdings (RANI) Gets a Buy From Stifel Nicolaus
HC Wainwright & Co. : The Rani Therapeutics Hldgs (RANI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $13.00.
HC Wainwright & Co. : The Rani Therapeutics Hldgs (RANI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $13.00.
HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $13
HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the price target from $12 to $13.
Rani Therapeutics Hldgs Q1 EPS $(0.29) Beats $(0.31) Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.31) by 6.45 percent. This is a 12.12 percent increase over losses
Rani Therapeutics | 10-Q: Quarterly report
Rani Therapeutics 1Q Loss/Shr 29c >RANI
Rani Therapeutics 1Q Loss/Shr 29c >RANI
Press Release: Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) -
BGC, DRS and AMTX Are Among After Hour Movers
Equifax Reports Weak Sales, Joins Synovus Financial And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday. Shares of Equifax Inc. (NYSE:EFX) fell sharply in today's pre-market trading after the company re
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e
Analysis
Price Target
No Data
